Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2

BACKGROUND: Breast Cancer Trials of Oral Everolimus 2 (BOLERO-2), a phase III study in postmenopausal women with estrogen receptor–positive breast cancer progressing despite nonsteroidal aromatase inhibitor therapy, showed statistically significant benefits with adding everolimus to exemestane. More...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Natl Cancer Inst
Main Authors: Gnant, Michael, Baselga, Jose, Rugo, Hope S., Noguchi, Shinzaburo, Burris, Howard A., Piccart, Martine, Hortobagyi, Gabriel N., Eakle, Janice, Mukai, Hirofumi, Iwata, Hiroji, Geberth, Matthias, Hart, Lowell L., Hadji, Peyman, El-Hashimy, Mona, Rao, Shantha, Taran, Tetiana, Sahmoud, Tarek, Lebwohl, David, Campone, Mario, Pritchard, Kathleen I.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6430494/
https://ncbi.nlm.nih.gov/pubmed/23425564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt026
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados